Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results.
To access the live and archived webcast, please visit the Investor Relations page of Spyre's website athttps://ir.spyre.com/events-and-presentations. The archived webcast will be available for a limited time on the Company's website.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
https://mma.prnewswire.com/media/2286436/Spyre_Therapeutics_Inc_Logo.jpg
https://c212.net/c/img/favicon.png?sn=DA11239&sd=2025-06-16
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-from-phase-1-healthy-volunteer-trials-for-its-spy002-program-its-novel-half-life-extended-anti-tl1a-antibodies-on-june-17-2025-302482779.html
SOURCE Spyre Therapeutics, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=DA11239&Transmission_Id=202506161605PR_NEWS_USPR_____DA11239&DateId=20250616